U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06897358) titled 'Leniolisib for Immune Dysregulation in CVID' on March 12.
Brief Summary: In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.
Study Start Date: Feb. 12
Study Type: INTERVENTIONAL
Condition:
Common Variable Immunodeficiency (CVID)
Intervention:
DRUG: Leniolisib
Planned ...